- Conditions
- HIV Infections
- Interventions
- ARV regimen, enfuvirtide [Fuzeon]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 103
- States / cities
- Phoenix, Arizona • Bakersfield, California • Berkeley, California + 78 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 13,760
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer, Nonsmall Cell Lung Cancer
- Interventions
- XMT-1592
- Biological
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin Degludec, Insulin Glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 18
- States / cities
- Anaheim, California • Lomita, California • Los Angeles, California + 15 more
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
- Interventions
- Oral MRT-2359
- Drug
- Lead sponsor
- Monte Rosa Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, ifosfamide, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
- Conditions
- Tourette Syndrome
- Interventions
- Valbenazine, Placebo oral capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 34
- States / cities
- Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
- Conditions
- Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Interventions
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Drug
- Lead sponsor
- CARGO Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more
- Conditions
- Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
- Interventions
- Levetiracetam, Keppra
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 60
- States / cities
- Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 25 Years
- Enrollment
- 5,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 203
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
- Conditions
- Corneal Epithelial Dystrophy
- Interventions
- Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 88 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2010
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Grade 2 Meningioma, Intracranial Meningioma
- Interventions
- Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Procedure · Other · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years to 89 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Beverly Hills, California • Campbell, California + 37 more
- Conditions
- Glioblastoma
- Interventions
- Not listed
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Sacramento, California • Miami, Florida + 16 more
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Crenolanib, Mitoxantrone, Cytarabine, Etoposide, Fludarabine, G-CSF, Idarubicin
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Duarte, California • Dallas, Texas + 1 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Palmitil, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more
- Conditions
- Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis
- Interventions
- Abetimus sodium (LJP 394)
- Drug
- Lead sponsor
- La Jolla Pharmaceutical Company
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 48 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- eltrombopag, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
- Conditions
- Saphenous Vein Graft Atherosclerosis
- Interventions
- Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label)
- Device · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
- Conditions
- Pruritus
- Interventions
- EP547, Placebo
- Drug
- Lead sponsor
- Escient Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 36 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK-2017357, Placebo tablets, Riluzole
- Drug · Other
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin lispro, Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Concord, California • Fresno, California + 30 more